Savaysa & Mortality Data & Updates Superiority Data!!!

Discussion in 'Daiichi-Sankyo' started by anonymous, Mar 19, 2016 at 9:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This will hit the news soon. I got wind of it.

    This just in! Wow!!! Huge, mega P-Value!!! .00001!!! Primary End Point, not a composite end point with A Superiority claim!!!

    The updated label will read: "To increase the mortality and morbidity of Edoxaban/Savaysa in AF and PE/DVT, also for the company, and those jobs aligned to it. It is Superior to all other Factor Xa's in this respect.
     

  2. anonymous

    anonymous Guest

    Savaysa is a fly on the butts of the two giants and market share leaders, xarelto and eliquis.
    It's a dog and it's dead to a majority of doctors who have the patients to use it. Sucks
     
  3. anonymous

    anonymous Guest

    Savaysa is just another stain on our very dirty underwear
     
  4. anonymous

    anonymous Guest

    p value LOL are you kidding me? I can't wait for this news to hit so I can laugh even harder
     
  5. anonymous

    anonymous Guest

    Read the OP "Label change" dope! Lol!
     
  6. anonymous

    anonymous Guest

     
  7. anonymous

    anonymous Guest

     
  8. anonymous

    anonymous Guest

    who's kidding who?